NEW YORK (GenomeWeb) – Investment firm Piper Jaffray last night upgraded its rating on Myriad Genetics' stock to overweight and increased its price target on the shares to $53, citing commercial payors' growing willingness to cover several tests in its portfolio.
To read the full story....
Register for Free....and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.